Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
about
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesNintedanib in NSCLC: evidence to date and place in therapyVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Systemic and targeted therapies for early-stage lung cancerEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysisSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateEffectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysisRandomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.ZEPHYR: failure of a "spring wind" in lung cancer.ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesA retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisQTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.Tyrosine kinase inhibitors in lung cancer.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trialsTargeted therapies for lung cancer: clinical experience and novel agentsRisk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabThe potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapyMolecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaCustomised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P2860
Q26745422-9D547443-56FB-4D86-A5A3-FEB96D42B92BQ26745424-4671CA88-5064-4187-BC1C-D14DE19CFBD7Q26770678-139A8C7B-9F89-4679-81D1-CD5AC1816DBFQ26775394-5C1306E1-3F91-41E0-8CE3-98D77683C317Q26865490-1FD5FD12-DCDC-40F2-BE92-2B1916DB7DD1Q26995204-78769E33-C194-423C-9C15-E52C1750D4BDQ27693185-9A9BEE0C-9D3A-4558-9F12-41D0740AFB2AQ28079328-E81038EC-3072-4ECD-A26A-D65D021AA926Q28085104-60EAA462-DE76-47E3-87B2-168A084ECC42Q28480930-C1605DBE-5E56-408D-B9F3-70ABAD982077Q30356434-262F0513-ACED-4438-A527-DA363A10D95FQ33399254-945F7E84-CB84-4C5D-96C3-D2E946D4BF6CQ33418555-3D64A678-4EE3-490E-A81D-F2AA0414E209Q33424852-D83F370C-C206-4C46-9BF6-3C5C54D4E11FQ33903078-4F283C1A-DB5D-4CB3-AC12-A8C323D3EE8AQ34316070-A3B52DF5-64E9-4DCB-8BF2-D2F06CA3926EQ34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550Q34826532-F4C9B420-54E1-4214-AE7A-C1A6796AE7EEQ35168766-36E6C754-4A7B-416E-8406-46CC0A45C3A6Q35187896-69DB1A3F-80E1-4A65-807F-F957713B5EA2Q35200470-CB4AB410-95CD-4668-90FC-92859985ED66Q35200483-E5B58895-95F6-4D51-ACD5-EE4388EF7A06Q35346839-D0FD1D82-01C8-44CD-BB81-935E5578FE2FQ35545693-50917C76-7D75-45B8-B5A8-D1663A1E48F9Q35632548-894BF2EB-FB30-440F-AEC5-E1E7F59CDD86Q35649624-56F07DB8-ABEC-42C2-B496-79F2AD2C974FQ35677270-8459DBE8-A816-4BAD-812E-B1495361E54EQ35908430-289EA833-B5B5-4643-AD0C-78650972CD75Q35966757-4DB9A767-28CF-4807-8B01-CEC02C1C2079Q36037036-09269790-40E5-4F76-9F5A-469061F600D0Q36054970-2EB7BA11-4F90-4A26-A0DD-BD5A3A42740FQ36301449-0B68EE9B-7DBF-43B4-82A8-1FA31E629F9AQ36630478-6D52D841-96AA-4596-83CB-29C8EE2E360FQ36729895-A21723B8-C29E-4650-94AB-0300D62DFA0FQ36738376-8355A2C3-A66D-48CD-8FD7-1586797A6C7CQ36811479-B9A4914B-8EDA-4EE8-A4E8-37054828FE64Q36859958-831EF8F4-EC12-4A0A-A3AA-6F7FCDD3D6E8Q36996220-73DC81F7-129E-4144-82D2-FB2C82A15525Q37042424-35B7FDDD-C866-4041-AE1F-F90E5FFE4307Q37246286-0B9F1DC0-8BCC-49E3-B3DD-38E1BCC0B1C0
P2860
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@en
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@nl
type
label
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@en
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@nl
prefLabel
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@en
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@nl
P2093
P356
P1476
Vandetanib plus pemetrexed for ...... double-blind phase III trial.
@en
P2093
Chih-Hsin Yang
Filippo de Marinis
Jessica Read
Johan F Vansteenkiste
Johann Raats
Jürgen Wolf
Maya Gottfried
Peter Langmuir
Raymond P Abratt
Richard H de Boer
P304
P356
10.1200/JCO.2010.29.5717
P407
P577
2011-01-31T00:00:00Z